<DOC>
	<DOCNO>NCT00398567</DOCNO>
	<brief_summary>The purpose study learn whether safe effective administer HKI-272 ( neratinib ) combination Herceptin patient advance breast cancer .</brief_summary>
	<brief_title>A Phase 1/2 Study Of HKI-272 ( Neratinib ) Combination With Trastuzumab ( Herceptin ) In Subjects With Advanced Breast Cancer</brief_title>
	<detailed_description>Open label phase 1/2 study ascend multiple oral dos HKI-272 combination IV Herceptin subject advance HER2+ breast cancer . Three six subject enrol dose group . Adverse event dose limit toxicity assess first dose study drug though day 21 . When maximum tolerate dose HKI-272 plus Herceptin determine , additional 30 subject enrol dose level , follow progression free survival approximately 1 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Pathologic diagnosis breast cancer current stage IIIB , IIIC IV curable available therapy Progression follow least one Herceptincontaining cytotoxic chemotherapy regimen ( neoadjuvant , adjuvant , metastatic setting ) HER2 positive breast cancer At least one measurable target lesion Adequate performance status Adequate cardiac , kidney , liver function Adequate blood count Willingness subject surgically sterile post menopausal use acceptable method birth control More 3 prior cytotoxic chemotherapy regimens locally advanced metastatic disease Major surgery , chemotherapy , radiotherapy , investigational agent , Herceptin cancer therapy within 2 week treatment day 1 Prior treatment anthracyclines cumulative dose &gt; 400 mg/m^2 Extensive visceral disease Active central nervous system metastases Pregnant breast feed woman Significant chronic recent acute gastrointestinal disorder diarrhea major symptom Prior exposure HKI272 HER2 target agent ( except Herceptin Tykerb ) Significant cardiac disease dysfunction History lifethreatening hypersensitivity Herceptin Inability unwillingness swallow HKI272 capsule Any cancer within 5 year exception contralateral breast cancer , adequately treated cervical carcinoma situ , adequately treat basal squamous cell carcinoma skin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HKI-272</keyword>
	<keyword>neratinib</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>Herceptin</keyword>
	<keyword>breast cancer</keyword>
</DOC>